AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01600365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ophthalmic gel (placebo)
Description: Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
Study NCT01600365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
Study NCT01404156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel
Description: NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous IV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2, PO BID (ECX)
Study NCT01404156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carboplatin paclitaxel plus concurrent radiotherapy
Description: 5 cycles carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29 preoperatively:~* paclitaxel: 50 mg / m2 IV over 1 hour~* carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion~Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~1. Dose specifications:~1. Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy. This total radiation dose option is acceptable if boost dose is not possible due to clinical reasons or dosimetric constraints.~2. Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment .
Study NCT01404377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infiltration with ropivacaine solution
Description: Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
Study NCT01741636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo Survivorship Care Planning
Study NCT01741636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01741636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00551187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V504
Description: V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
Study NCT00551187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
Study NCT02572076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motus Cleansing System
Study NCT05982483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae plane block using 20 ml of bupivicaine 0.25%
Description: Utilizing the in line approach, a 22 gauge 3.5 spinal needle was guided the the tip of the transverse process corresponding to the area of maximal tenderness or central to the reported area of spasm. 1% lidocaine with epinephrine was used for skin anaesthesia and for hydro-localization of the needle tip on approach to the tip of the transverse process. Once the needle tip made contact with the transverse process, 2-3 ml of 1% lidocaine with epinephrine was injected to open the ESP plane. If there was no reported tachycardia after approximately 45 seconds, 20 ml of 0.25% bupivicaine was injected into the ESP plane.
Study NCT05982483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Analgesia as dictated by the treating emergency physician
Study NCT00166543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-108
Study NCT02453334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectafer
Study NCT02453334 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT01444859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo for 10 weeks
Study NCT03403426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wingman Crossing Catheter
Description: Endovascular CTO crossing
Study NCT01763580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral
Study NCT01763580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral
Study NCT01763580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral
Study NCT00551187 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
Study NCT00551187 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: V504 Placebo in 3 dose regimen for 6 month treatment period.
Study NCT03374917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: powder for solution
Study NCT00693498 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard leukoreduced irradiated blood cell transfusion
Description: standard vs washed blood cell transfusions
Study NCT00693498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Washed leukoreduced irradiated blood cell transfusions
Description: washed leukoreduced irradiated blood cell transfusions
Study NCT03625765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartGoggles
Description: the system is wearable and simulates natural binocular human vision, which minimizes the training curve for new users. The wide-field stereoscopic imaging allows clinicians to rapidly determine the extent of lesions and the hand-held microscopy probe assist clinician to visualize the lesions with high resolution.
Study NCT01259804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Description: Daily doses of peanut flour
Study NCT04989127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
Study NCT04989127 — intervention group
Intervention type: PROCEDURE
Intervention: traditional osteotomies
Description: In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
Study NCT04989127 — intervention group
Intervention type: BIOLOGICAL
Intervention: Platelet Rich Fibrin
Description: Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
Study NCT04989127 — intervention group
Intervention type: DRUG
Intervention: Antibiotics, Penicillin
Description: Antibiotics are prescribed for the patients.
Study NCT04989127 — intervention group
Intervention type: DRUG
Intervention: Analgesic
Description: Analgesics are prescribed for the patients.
Study NCT04989127 — intervention group
Intervention type: DRUG
Intervention: Antibiotic
Description: Patients with penicillin allergy
Study NCT02844699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobilan (M-VM3)
Description: Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
Study NCT02844699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% infusion solution of dextrose (glucose)
Study NCT02844699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% infusion solution of dextrose (glucose)
Study NCT03757221 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ixazomib and Daratumumab
Description: Daratumumab will be administrated every week for the first 2 cycles. For cycle 3 to 6, it will be administrated every two weeks at day 1 and day 15. From cycle 7 until progression Daratumumab will be administrated every 4 weeks.~Ixazomib will be administrated every week three weeks on one week off at D1, D8 and D15 on a 28-d cycle basis.~Dexamethasone will not be given except one series of 4 days of dexamethasone, 20 mg/day or a maximum of 80 mg, for emergencies and complications at initiation of treatment.
Study NCT03520400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.
Study NCT03375502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varicella Vaccine
Description: The subject will receive investigational product or comparator.
Study NCT03375502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varicella Vaccine
Description: The subject will receive investigational product or comparator.
Study NCT04686786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-865
Description: Participants will receive 25 mg CVL-865 tablets orally BID during the treatment period. The dose may be decreased to 17.5 mg BID for tolerability.
Study NCT03534310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
Study NCT03534310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification
Study NCT03534310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Study NCT03534310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Study NCT03034343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Study NCT02323984 — intervention group
Intervention type: OTHER
Intervention: miRNA Testing, Microemboli Monitoring, Delirium Assessment
Description: Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).
Study NCT02464800 — intervention group
Intervention type: PROCEDURE
Intervention: Vitrectomy for proliferative diabetic retinopathy
Description: 25-gauge vitrectomy
Study NCT01622244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-ordinated Access to Care from Hospital Emergency Departments
Description: brief, intensive case management for frequent users of hospital Emergency Departments who have mental health and/or addictions problems
Study NCT01598233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silimed Intragastric balloon
Description: Intragastric balloon inflated with 650 ml of NaCl 0.9% mixed with 20 ml of methylene blue solution
Study NCT03195725 — intervention group
Intervention type: OTHER
Intervention: Review of notes
Description: No intervention will occur
Study NCT01622244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated Access to Care from Hospital Emergency Departments
Description: Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
Study NCT01622244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling and Resource Education
Description: Participants will receive usual care as well as an educational session and resource guide outlining community-based services
Study NCT02347657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661 Plus Ivacaftor Combination
Description: FDC tablet, oral use
Study NCT02347657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet, oral use
Study NCT02347657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VX-661 Plus Ivacaftor Combination Placebo
Description: FDC tablet, oral use
Study NCT02347657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor placebo
Description: Tablet, oral use
Study NCT01455207 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological testing
Description: assessment of memory, executive functions and ataxia
Study NCT01455207 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood draw
Description: hepatic markers, red blood markers and vitamin markers
Study NCT01455207 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: genetic testing
Description: genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)
Study NCT04103905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Monoclonal Antibody MIL62 Injection
Description: The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
Study NCT01455207 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brain imaging examination
Description: MRI, DTI and PET examinations
Study NCT04482543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Intra-silicone oil injection of 250 µg methotrexate is done at the end of surgery and is repeated at weeks 3 and 6 postoperatively.
Study NCT03469284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given standard of care therapy
Study NCT01520285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zanidip
Description: Lercanidipine hydrochloride (10mg/tablet)once per day
Study NCT01891513 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise
Description: All participants will take part in 3 days/week of structured aerobic, stretching, and balance training for weeks 1-12. For weeks, 13-24, training will be reduced to 2 days/week and a resistance training component added. Participants will also be expected to engage in 2 bouts of 30 minutes of home-based walking per week.
Study NCT01891513 — intervention group
Intervention type: DRUG
Intervention: ACE inhibitor + exercise
Description: In addition to exercise training, participants will receive an initial perindopril dose of 2 mg/day which will be titrated to 4 mg/day.
Study NCT01891513 — intervention group
Intervention type: DRUG
Intervention: Thiazide diuretic + exercise
Description: In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
Study NCT01891513 — intervention group
Intervention type: DRUG
Intervention: Angiotensin receptor blocker + exercise
Description: In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
Study NCT01399723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Oral 45mg/kg 12 hourly
Study NCT01399723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzyl penicillin
Description: Intravenous 50,000IU/kg 6 hourly
Study NCT01520285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Felodipine sustained-release tablet
Description: Felodipine sustained-release tablet (5mg/tablet)
Study NCT01695525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
Study NCT03469284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Given standard of care therapy
Study NCT01976650 — intervention group
Intervention type: DRUG
Intervention: dexamethasone 700 ㎍ intravitreal implant
Description: dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
Study NCT03469284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Given lower dose PO
Study NCT03469284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Given medium dose PO
Study NCT03469284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Given higher dose PO
Study NCT02447289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Description: Ketamine injectable solution in a concentration of 50.0 mg/mL administered into the nose with an atomizer; dose of 4.0 mg/kg, maximum 100.0 mg
Study NCT02447289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ketamine
Description: Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
Study NCT02447289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: Midazolam injectable solution in a concentration of 5.0 mg/mL administered into the nose with an atomizer; dose of 0.2 mg/kg, maximum 5.0 mg
Study NCT02447289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral midazolam
Description: Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine; dose of 1.0 mg/kg, maximum 20.0 mg when give as a solely agent
Study NCT02132598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Study NCT05046652 — intervention group
Intervention type: BIOLOGICAL
Intervention: Convalescent Plasma Therapy
Description: In this study, eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320.
Study NCT04506255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone tape
Description: Medical grade tape with silicone adhesive
Study NCT02515565 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cephalosporin with or without erythromycin
Description: Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
Study NCT02515565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy program
Description: The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes added to the standard medical treatment. I will include breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.